Skip to main content


For a full list of our publications, please visit PubMed.

  1. Song X, Tiek D, Miki S, Huang T, Lu M, Goenka A, Iglesia RP, Yu X, Wu R, Walker MN  et al.  RNA splicing analysis deciphers developmental hierarchies and reveals therapeutic targets in adult glioma.  J Clin Invest  2024 Apr 25;. pii:e173789
  2. Kim DR, Orr MJ, Yu X, Munshi HH, Wang A, Trudeau C, Kwong AJ, Cheng SY, Scheidt KA  Synthesis and Structural Optimization of ATG4B Inhibitors for the Attenuation of Autophagy in Glioblastoma.  ACS Med Chem Lett  2024 Feb 08;15(2):258-264. doi:10.1021/acsmedchemlett.3c00505
  3. Bhutada I, Khambati F, Cheng SY, Tiek DM, Duckett D, Lawrence H, Vogelbaum MA, Mo Q, Chellappan SP, Padmanabhan J  CDK7 and CDK9 inhibition interferes with transcription, translation, and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity.  Neuro Oncol  2024 Jan 05;26(1):70-84. doi:10.1093/neuonc/noad143
  4. Sun MA, Yang R, Liu H, Wang W, Song X, Hu B, Reynolds N, Roso K, Chen LH, Greer PK  et al.  Repurposing Clemastine to Target Glioblastoma Cell Stemness.  Cancers (Basel)  2023 Sep 18;15(18). pii:4619
  5. Goenka A, Song X, Tiek D, Iglesia RP, Lu M, Zeng C, Horbinski C, Zhang W, Hu B, Cheng SY  Oncogenic long noncoding RNA LINC02283 enhances PDGF receptor A-mediated signaling and drives glioblastoma tumorigenesis.  Neuro Oncol  2023 Sep 05;25(9):1592-1604. doi:10.1093/neuonc/noad065
  6. Zeng C, Song X, Zhang Z, Cai Q, Cai J, Horbinski C, Hu B, Cheng SY, Zhang W  Dissection of transcriptomic and epigenetic heterogeneity of grade 4 gliomas: implications for prognosis.  Acta Neuropathol Commun  2023 Aug 14;11(1):133. pii:133
  7. Cai Q, Zhang Z, Cui X, Zeng C, Cai J, Cai J, Wu K, Zhang X, Shi Y, Arvanitakis Z  et al.  PETCH-DB: a Portal for Exploring Tissue-specific and Complex disease-associated 5-Hydroxymethylcytosines.  Database (Oxford)  2023 Jun 10;2023. pii:baad042
  8. Getu AA, Zhou M, Cheng SY, Tan M  The mammalian Sterile 20-like kinase 4 (MST4) signaling in tumor progression: Implications for therapy.  Cancer Lett  2023 Jun 01;563:216183. doi:10.1016/j.canlet.2023.216183
  9. Tiek D, Wells CI, Schröder M, Song X, Alamillo-Ferrer C, Goenka A, Iglesia R, Lu M, Hu B, Kwarcinski F  et al.  SGC-CLK-1: A chemical probe for the Cdc2-like kinases CLK1, CLK2, and CLK4.  Curr Res Chem Biol  2023;3. pii:100045
  10. McCord M, Bartom E, Burdett K, Baran A, Eckerdt FD, Balyasnikova IV, McCortney K, Sears T, Cheng SY, Sarkaria JN  et al.  Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts.  Cancers (Basel)  2022 Nov 09;14(22). pii:5494
  11. Goenka A, Cheng SY  Targeting neddylation in cancer.  Neuro Oncol  2022 Nov 02;24(11):1869-1870. doi:10.1093/neuonc/noac159
  12. Goenka A, Tiek DM, Song X, Iglesia RP, Lu M, Hu B, Cheng SY  The Role of Non-Coding RNAs in Glioma.  Biomedicines  2022 Aug 20;10(8). pii:2031
  13. Tiek DM, Erdogdu B, Razaghi R, Jin L, Sadowski N, Alamillo-Ferrer C, Hogg JR, Haddad BR, Drewry DH, Wells CI  et al.  Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas.  Sci Adv  2022 Jun 24;8(25):eabn3471. pii:eabn3471
  14. Iglesia RP, Prado MB, Alves RN, Escobar MIM, Fernandes CFL, Fortes ACDS, Souza MCDS, Boccacino JM, Cangiano G, Soares SR  et al.  Unconventional Protein Secretion in Brain Tumors Biology: Enlightening the Mechanisms for Tumor Survival and Progression.  Front Cell Dev Biol  2022;10:907423. pii:907423
  15. Tiek D, Cheng SY  DNA damage and metabolic mechanisms of cancer drug resistance.  Cancer Drug Resist  2022;5(2):368-379. doi:10.20517/cdr.2021.148
  16. Tiek DM, Cheng SY  New life for an old therapy: ELTD1 as a downstream target of angiogenesis.  Neuro Oncol  2022 Mar 12;24(3):412-413. doi:10.1093/neuonc/noab286
  17. Yu B, Luo F, Sun B, Liu W, Shi Q, Cheng SY, Chen C, Chen G, Li Y, Feng H  KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer.  Adv Sci (Weinh)  2021 Oct;8(20):e2100014. pii:2100014
  18. Song L, Lin C, Gong H, Wang C, Liu L, Wu J, Tao S, Hu B, Cheng SY, Li M  et al.  Author Correction: miR-486 sustains NF-κB activity by disrupting multiple NF-κB-negative feedback loops.  Cell Res  2021 Oct;31(10):1138. doi:10.1038/s41422-021-00549-y
  19. Cai J, Zeng C, Hua W, Qi Z, Song Y, Lu X, Li D, Zhang Z, Cui X, Zhang X  et al.  An integrative analysis of genome-wide 5-hydroxymethylcytosines in circulating cell-free DNA detects noninvasive diagnostic markers for gliomas.  Neurooncol Adv  2021;3(1):vdab049. pii:vdab049
  20. Huang T, Cheng SY  Targeting phospholipid metabolism for glioblastoma therapy.  Neuro Oncol  2021 Mar 25;23(3):343-344. doi:10.1093/neuonc/noaa309
  21. Huang T, Yang Y, Song X, Wan X, Wu B, Sastry N, Horbinski CM, Zeng C, Tiek D, Goenka A  et al.  PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells.  Mol Cell  2021 Mar 18;81(6):1276-1291.e9. doi:10.1016/j.molcel.2021.01.015
  22. Gao X, Xia X, Li F, Zhang M, Zhou H, Wu X, Zhong J, Zhao Z, Zhao K, Liu D  et al.  Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling.  Nat Cell Biol  2021 Mar;23(3):278-291. doi:10.1038/s41556-021-00639-4
  23. Goenka A, Tiek D, Song X, Huang T, Hu B, Cheng SY  The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma.  Cells  2021 Feb 24;10(3). pii:484
  24. Luo JH, Liu S, Tao J, Ren BG, Luo K, Chen ZH, Nalesnik M, Cieply K, Ma T, Cheng SY  et al.  Pten-NOLC1 fusion promotes cancers involving MET and EGFR signalings.  Oncogene  2021 Feb;40(6):1064-1076. doi:10.1038/s41388-020-01582-8
  25. Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, Abeliovich H, Abildgaard MH, Abudu YP, Acevedo-Arozena A  et al.  Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1.  Autophagy  2021 Jan;17(1):1-382. doi:10.1080/15548627.2020.1797280